Mymetics Corporation Information to be Available Through Standard & Poor’s Market Access Program

    NYON, Switzerland, August 25 /
EMWNews
/ -- Mymetics

Corporation (OTCBB:MYMX) announced today that its company information will

be made available via Standard & Poor's Market Access Program, an

information distribution service that enables subscribing publicly traded

companies to have their company information disseminated to users of

Standard & Poor's Advisor Insight. The company information to be made

available through this program includes share price, volume, dividends,

shares outstanding, company financial position, and earnings. Standard &

Poor's Advisor Insight is an Internet-based research engine used by more

than 100,000 investment advisors. A public version of the site is available

at http://www.advisorinsight.com.



    In addition, information about companies in Standard & Poor's Market

Access Program will be available via S&P's Stock Guide database, which is

distributed electronically to virtually all major quote vendors. As part of

the program, a full description of Mymetics Corporation will also be

published in the Daily News section of Standard Corporation Records, a

recognized securities manual for secondary trading in approximately 38

states under their Blue Sky Laws.



    Company information distributed through the Market Access Program is

based upon information that Standard & Poor's considers to be reliable, but

neither Standard & Poor's nor its affiliates warrant its completeness or

accuracy, and it should not be relied upon as such. This material is not

intended as an offer or solicitation for the purchase or sale of any

security or other financial instrument.



    Mymetics have further contracted with BlueSkyMLS

http://www.blueskymls.com to seek registration in states not covered by the

S&P Market Access Program.



    Ernest Luebke, Chief Financial Officer of Mymetics Corporation stated

"We are very pleased with the level of professionalism demonstrated by

Standard & Poor's as well as BlueSkyMLS in assisting us with our US

exemption process."

    About Mymetics Corporation



    Mymetics' primary objective is to develop vaccines and therapies to

prevent and treat the effects of certain retroviruses and other infectious

diseases, including the human immunodeficiency virus, or HIV, the virus

that leads to acquired immunodeficiency syndrome, or AIDS. Mymetics has

also recently acquired from a close scientific partner an advanced malaria

vaccine project currently in phase Ib clinical trial. Additional

applications of Mymetics's research include potential treatments and/or

vaccines for human oncoviral leukemias, multiple sclerosis, and organ

transplantation.






    Contacts:



    Anthony Jessop

    Senior Vice President Mymetics, Inc.

    tel: North America +1-303-800-6606

    [email protected]



    Standard & Poor's Customer Contact:

    Richard Albanese

    +1-212-438-3647

    [email protected]



    Standard and Poor's Media Relations Contact:

    Michael Privitera

    +1-212-438-6679

    [email protected]



    BlueSkyMLS Contact :

    Theodore J. Dragon

    +1-201-804-3909 x 113

    [email protected]